Reported positions
Quarter-end holdings as filed
Explore the full published position list and its source filing. This record excludes the manager’s cash, shorts and non-13(f) assets.
TANG CAPITAL MANAGEMENT LLC
A quarter-end snapshot. Filed up to 45 days later, so this page is not current holdings and never a complete portfolio. what a 13F is — and is not ↓ · methodology §13F ↗
Period
$2.0B
reported valuesum of disclosed values for 2026-03-31; 0 positions carry a NULL value and are excluded from the sum, surfaced here rather than folded away
51
positionsALL retained default holdings for this (filer, period), including NULL-value ones
4
new stakespositions with no comparable holding in the prior quarter (kind new), 2026-03-31
28
exitspositions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record
Position changes — into 2026-03-31
by shares · Δ value · filing link · how changes are classified §Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
AURINIA PHARMACEUTICALS INC COMposition key pos:11783 · issuer key iss:273 | add | +$536K | +900,000 | $181M | $181M | 11,329,500 | 12,229,500 | |
GALAPAGOS NV SPON ADRposition key sid:sec:prov:856d00daa392df84ca63299ef03992d5 · issuer key cusip6:36315X | trim | −$14.6M | −135,228 | $128M | $114M | 3,921,219 | 3,785,991 | |
STATE STR SPDR S&P 500 ETF T TR UNITposition key pos:12423 · issuer key iss:1897 | add | +$88.8M | +138,000 | $20.5M | $109M | 30,000 | 168,000 | |
CAPRICOR THERAPEUTICS INC COM NEWposition key sid:sec:prov:f5ab5fc62f8ffc42012ac685dc8651c0 · issuer key cusip6:14070B | add | +$54.3M | +1,699,900 | $49.1M | $103M | 1,700,000 | 3,399,900 | |
IMMUNOCORE HLDGS PLC ADSposition key pos:16434 · issuer key iss:1166 | add | −$11.4M | +20,830 | $91.2M | $79.9M | 2,628,538 | 2,649,368 | |
ANAPTYSBIO INC COMposition key pos:18179 · issuer key iss:200 | trim | +$9.2M | −1,208 | $64.6M | $73.8M | 1,332,087 | 1,330,879 | |
CORCEPT THERAPEUTICS INC COMposition key pos:16992 · issuer key iss:652 | add | +$55.0M | +1,343,236 | $5.5M | $60.5M | 156,764 | 1,500,000 | |
ANI PHARMACEUTICALS INC COMposition key pos:13977 · issuer key iss:27 | add | +$16.4M | +226,063 | $38.0M | $54.4M | 481,437 | 707,500 | |
INSMED INC COM PAR $.01position key pos:15087 · issuer key iss:1181 | add | +$32.1M | +200,000 | $10.4M | $42.5M | 60,000 | 260,000 | |
PRECIGEN INC COMposition key pos:17844 · issuer key cusip6:74017N | add | +$1.4M | +800,000 | $23.5M | $24.8M | 5,617,500 | 6,417,500 | |
COMPASS PATHWAYS PLC SPONSORED ADSposition key sid:sec:prov:88f799da4526ad1ae0a440740a6e9c1b · issuer key cusip6:20451W | new | +$22.1M | +4,002,200 | $0 | $22.1M | — | 4,002,200 | |
CRESCENT BIOPHARMA INC. COMposition key pos:17611 · issuer key iss:2481 | add | +$11.0M | +287,602 | $10.3M | $21.3M | 872,398 | 1,160,000 | |
NUVATION BIO INC COM CL Aposition key pos:13742 · issuer key iss:1597 | trim | −$21.1M | −707,900 | $34.6M | $13.5M | 3,857,457 | 3,149,557 | |
JOURNEY MED CORP COMposition key sid:sec:prov:11c9c773fc5f030a2e5092fe0f04e997 · issuer key cusip6:48115J | trim | −$6.7M | −244,596 | $14.3M | $7.6M | 1,854,596 | 1,610,000 | |
JANUX THERAPEUTICS INC COMposition key sid:sec:prov:7f79da9ff584753bfd1b9acc24c00236 · issuer key cusip6:47103J | new | +$7.0M | +500,000 | $0 | $7.0M | — | 500,000 | |
ARVINAS INC COMposition key pos:12209 · issuer key iss:250 | trim | −$1.0M | −31,040 | $6.8M | $5.7M | 569,698 | 538,658 | |
PMV PHARMACEUTICALS INC COMposition key sid:sec:prov:325eed3e19d59a984be6eb2201e2d894 · issuer key cusip6:69353Y | trim | −$911K | −694,915 | $6.2M | $5.3M | 4,940,000 | 4,245,085 | |
MODERNA INC COMposition key pos:13354 · issuer key iss:1490 | trim | −$15.4M | −592,820 | $20.4M | $5.1M | 692,820 | 100,000 | |
LENZ THERAPEUTICS INC COMposition key sid:sec:prov:37d3b7d0376e44b079f1262ff7392888 · issuer key cusip6:52635N | trim | −$9.7M | −414,055 | $13.8M | $4.1M | 865,169 | 451,114 | |
AGIOS PHARMACEUTICALS INC COMposition key pos:14037 · issuer key cusip6:00847X | new | +$3.4M | +100,000 | $0 | $3.4M | — | 100,000 | |
ERASCA INC COMposition key pos:12600 · issuer key iss:846 | trim | −$112K | −700,000 | $3.3M | $3.2M | 900,000 | 200,000 | |
COHERUS ONCOLOGY INC COMposition key sid:sec:prov:fb282388a58c6265f871891455dcfcbb · issuer key cusip6:19249H | trim | −$680K | −837,761 | $3.9M | $3.2M | 2,724,509 | 1,886,748 | |
ALTIMMUNE INC COM NEWposition key sid:sec:prov:6a2dba0acbb42028c25d866c026c78de · issuer key cusip6:02155H | trim | −$5.6M | −1,465,285 | $7.7M | $2.1M | 2,131,307 | 666,022 | |
EVOLUS INC COMposition key sid:sec:prov:3c1bdde45f78766466db92da273259f5 · issuer key cusip6:30052C | trim | −$6.3M | −762,671 | $8.3M | $2.0M | 1,245,692 | 483,021 | |
ABEONA THERAPEUTICS INC COM NEWposition key sid:sec:prov:714d680633cb6e30dfa6e0d524e9cebd · issuer key cusip6:00289Y | trim | −$3.5M | −600,000 | $5.3M | $1.8M | 1,000,000 | 400,000 | |
NEUMORA THERAPEUTICS INC. COMposition key sid:sec:prov:87e5cb91aeaa35f0c2f2443d9f9aa785 · issuer key cusip6:640979 | trim | −$874K | −527,357 | $1.7M | $858K | 967,235 | 439,878 | |
LEXICON PHARMACEUTICALS INC COM NEWposition key sid:sec:prov:3de8946eed46444b94fd5342eaddeac0 · issuer key cusip6:528872 | new | +$624K | +399,700 | $0 | $624K | — | 399,700 | |
| pos:11021 | exit‡e | −$9.8M | −1,400,000 | $9.8M | $0 | 1,400,000 | — | |
| pos:11430 | exit‡e | −$36.3M | −80,000 | $36.3M | $0 | 80,000 | — | |
| pos:12241 | exit‡e | −$15.4M | −23,331 | $15.4M | $0 | 23,331 | — | |
| pos:12513 | exit‡e | −$12.7M | −275,000 | $12.7M | $0 | 275,000 | — | |
| pos:14035 | exit‡e | −$8.3M | −1,069,810 | $8.3M | $0 | 1,069,810 | — | |
| pos:14079 | exit‡e | −$2.2M | −21,880 | $2.2M | $0 | 21,880 | — | |
| pos:14335 | exit‡e | −$10.9M | −290,292 | $10.9M | $0 | 290,292 | — | |
| pos:14561 | exit‡e | −$1.6M | −140,000 | $1.6M | $0 | 140,000 | — | |
| pos:14969 | exit‡e | −$2.0M | −40,000 | $2.0M | $0 | 40,000 | — | |
| pos:14993 | exit‡e | −$7.5M | −349,220 | $7.5M | $0 | 349,220 | — | |
| pos:15541 | exit‡e | −$1.2M | −15,640 | $1.2M | $0 | 15,640 | — | |
| pos:15894 | exit‡e | −$10.8M | −200,000 | $10.8M | $0 | 200,000 | — | |
| pos:15962 | exit‡e | −$6.2M | −800,000 | $6.2M | $0 | 800,000 | — | |
| pos:16027 | exit‡e | −$6.2M | −8,000 | $6.2M | $0 | 8,000 | — | |
| pos:16535 | exit‡e | −$23.8M | −127,788 | $23.8M | $0 | 127,788 | — | |
| pos:16974 | exit‡e | −$14.7M | −300,000 | $14.7M | $0 | 300,000 | — | |
| pos:18375 | exit‡e | −$6.6M | −351,252 | $6.6M | $0 | 351,252 | — | |
| pos:18414 | exit‡e | −$4.6M | −2,333,333 | $4.6M | $0 | 2,333,333 | — | |
| pos:18617 | exit‡e | −$26.7M | −700,000 | $26.7M | $0 | 700,000 | — | |
| pos:18889 | exit‡e | −$8.0M | −300,000 | $8.0M | $0 | 300,000 | — | |
| sid:sec:prov:055a2567de67e3d96ef1117e9fce8ec2 | exit‡e | −$51.9K | −6,158 | $51.9K | $0 | 6,158 | — | |
| sid:sec:prov:0e361d30324f107464e8c1d4734fc7e8 | exit‡e | −$25.4M | −2,814,000 | $25.4M | $0 | 2,814,000 | — | |
| sid:sec:prov:39d93878365e006cfbf0af4c0560d7f2 | exit‡e | −$46.1K | −46,131 | $46.1K | $0 | 46,131 | — | |
| sid:sec:prov:6a1de202689437ba5ea3d3a29fa60708 | exit‡e | −$8.6M | −556,359 | $8.6M | $0 | 556,359 | — | |
| sid:sec:prov:96105f9c4a049e845d3fa818880fba2d | exit‡e | −$14.0K | −7,073 | $14.0K | $0 | 7,073 | — | |
| sid:sec:prov:c4149a9e14976bb08df8d6a0cb6dd6b6 | exit‡e | −$1.6M | −139,617 | $1.6M | $0 | 139,617 | — | |
| sid:sec:prov:cc436d9af4067ff4382c62284d4ff9e5 | exit‡e | −$912K | −34,631 | $912K | $0 | 34,631 | — | |
| sid:sec:prov:fc7c842ed91a7e3b374f2a94cbad8d9a | exit‡e | −$64.9M | −900,000 | $64.9M | $0 | 900,000 | — |
35 more changes below.
Mark-to-market only (no share change) · 24
Positions whose share count is identical in both quarters; the value changed with price, not with a decision.
Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
CELCUITY INC COMposition key pos:11232 · issuer key iss:542 | no change | +$15.1M | 0 | $105M | $120M | 1,050,000 | 1,050,000 | |
MIRUM PHARMACEUTICALS INC COMposition key pos:12357 · issuer key iss:1485 | no change | +$16.6M | 0 | $97.6M | $114M | 1,236,027 | 1,236,027 | |
KINIKSA PHARMACEUTICALS INTL ORD SHS CL Aposition key pos:14218 · issuer key iss:2550 | no change | +$15.6M | 0 | $93.2M | $109M | 2,259,889 | 2,259,889 | |
PTC THERAPEUTICS INC COMposition key pos:18526 · issuer key iss:1662 | no change | −$11.7M | 0 | $114M | $102M | 1,500,000 | 1,500,000 | |
SPYRE THERAPEUTICS INC COM NEWposition key pos:14500 · issuer key iss:82 | no change | +$33.5M | 0 | $62.0M | $95.4M | 1,892,200 | 1,892,200 | |
KALVISTA PHARMACEUTICALS INC COMposition key pos:10966 · issuer key cusip6:483497 | no change | +$18.2M | 0 | $73.9M | $92.1M | 4,573,530 | 4,573,530 | |
COMPASS THERAPEUTICS INC COMposition key sid:sec:prov:c5f3f37de4d48fd1b29c266e9a76eb0b · issuer key cusip6:20454B | no change | −$1.3M | 0 | $90.2M | $88.8M | 16,790,809 | 16,790,809 | |
TARSUS PHARMACEUTICALS INC COMposition key pos:11454 · issuer key iss:2092 | no change | −$13.9M | 0 | $97.3M | $83.4M | 1,188,624 | 1,188,624 | |
BIONTECH SE SPONSORED ADSposition key pos:16026 · issuer key iss:380 | no change | −$3.0M | 0 | $44.7M | $41.8M | 470,000 | 470,000 | |
VIRIDIAN THERAPEUTICS INC COMposition key sid:sec:prov:4b145c10f034612809a5ead021971789 · issuer key cusip6:92790C | no change | −$20.7M | 0 | $55.8M | $35.1M | 1,792,626 | 1,792,626 | |
ATEA PHARMACEUTICALS INC COMposition key sid:sec:prov:59d0b0eafecf175026d132907aed2349 · issuer key cusip6:04683R | no change | +$8.7M | 0 | $17.2M | $25.9M | 4,814,700 | 4,814,700 | |
DIANTHUS THERAPEUTICS INC COMposition key pos:18462 · issuer key iss:731 | no change | +$11.3M | 0 | $10.9M | $22.2M | 264,692 | 264,692 | |
STOKE THERAPEUTICS INC COMposition key sid:sec:prov:3fee4169345e05a49cf14bcc2babfc71 · issuer key cusip6:86150R | no change | +$410K | 0 | $15.9M | $16.3M | 500,000 | 500,000 | |
VIKING THERAPEUTICS INC COMposition key pos:17730 · issuer key iss:2273 | no change | −$1.3M | 0 | $17.6M | $16.3M | 500,000 | 500,000 | |
IDEAYA BIOSCIENCES INC COMposition key sid:sec:prov:f7d48a640772d3aa60939ca4949078c5 · issuer key cusip6:45166A | no change | −$563K | 0 | $15.6M | $15.0M | 450,000 | 450,000 | |
PLIANT THERAPEUTICS INC COMposition key pos:14964 · issuer key cusip6:729139 | no change | +$246K | 0 | $7.5M | $7.7M | 6,143,132 | 6,143,132 | |
BIOGEN INC COMposition key pos:12302 · issuer key iss:376 | no change | +$257K | 0 | $6.2M | $6.4M | 35,000 | 35,000 | |
UROGEN PHARMA LTD COMposition key sid:sec:prov:a469da6cabfc03832e3d85a7bff09e97 · issuer key cusip6:M96088 | no change | −$1.9M | 0 | $8.2M | $6.3M | 350,000 | 350,000 | |
HERON THERAPEUTICS INC COMposition key sid:sec:prov:bf8ba8a176478fa55a6137c9e08e0ee6 · issuer key cusip6:427746 | no change | −$3.1M | 0 | $8.1M | $5.0M | 6,250,000 | 6,250,000 | |
KEZAR LIFE SCIENCES INC COM NEWposition key sid:sec:prov:b6b50028a2ad8d2a67e01abc2d70052f · issuer key cusip6:49372L | no change | +$751K | 0 | $4.2M | $4.9M | 664,314 | 664,314 | |
WAVE LIFE SCIENCES LTD SHSposition key pos:15162 · issuer key iss:2734 | no change | −$5.9M | 0 | $10.2M | $4.4M | 600,000 | 600,000 | |
NKARTA INC COMposition key sid:sec:prov:d87c40180b837190c93dcee0de07232d · issuer key cusip6:65487U | no change | +$385K | 0 | $2.7M | $3.1M | 1,480,823 | 1,480,823 | |
FATE THERAPEUTICS INC COMposition key sid:sec:prov:4d3637158067a06dca4ed69ca356c5a7 · issuer key cusip6:31189P | no change | +$254K | 0 | $1.1M | $1.4M | 1,167,773 | 1,167,773 | |
ROCKET PHARMACEUTICALS INC COMposition key sid:sec:prov:5db085c4e925ed01a4a1cbc6ba09d304 · issuer key cusip6:77313F | no change | +$7.0K | 0 | $351K | $358K | 100,000 | 100,000 |
Quarter ended 2026-03-31Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.
Changes derive from the aggregate's top-25 slices and keyable positions only; unkeyable holdings are counted in the registry, not differenced. methodology §13F ↗
Book shape
2026-03-31 · concentration · vs tracked median · tick = median- Top-25 concentration
- 93.1%above median 80.0%
- Concentration index
- 458 bpsabove median 446 bps
- Positions with value
- 51 / 51median book 97.5 positions
Concentration uses reported 13F long value, not total assets. The index is withheld when any position lacks a value. Medians are over the 8,748 tracked filers with a 2026-03-31 book; the index median over the 8,662 with a complete book.
null-value positions: 0holdings whose <value> did not parse — retained and counted, never zero-filled · top-N share ·§: 93.1% · HHI (bps) ·§: 458integer Herfindahl–Hirschman index in basis points over disclosed position values · QoQ moves: 79
Filing history
AVAILABLE QUARTERS| Period | Source |
|---|---|
| 2026-03-31 | EDGAR ↗ |
PLANNED sector rotation · Congress overlap · signals for this filer
Complete source filings on SEC EDGAR
The complete filing on EDGAR.
The position list above is served from the published Public Filings build — every position this filer reported for the selected quarter, as it reported it. This block is provenance, not a substitute: the filing itself is the record, and it is one click away. Serving this list is M2-CONTRACT §3, amended 2026-08-02; §3.1 keeps live EDGAR for filings newer than this build.
Open TANG CAPITAL MANAGEMENT LLC's 13F filings on SEC EDGAR ↗Notes on this data
Share changes
Compare consecutive quarters
Position changes retain the producer’s classification and comparability flags. Share counts and reported values describe different changes.
Coverage
A snapshot, not current holdings
Use the quarter selector to inspect available periods. Unknown values stay unknown and each table states its coverage.
ViewPrior quarter not yet availableThis build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.
Reported positions — 2026-03-31
1–51 of 51 positions · $2.0B disclosed value over 51 rows · 0 undisclosed-value rowsEvery row below carries ticker not yet mapped — stated once here rather than repeated on every row.
| KindClassification is not joined into this reported-position view. Use the changed-positions view to compare the two published quarters. | TickerThis list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names. | Issuera position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing | WeightShare of total reported value, calculated only when the full position list has disclosed values. This is 13F long value, not total assets. | Valuevalue undisclosed on the filing: retained and counted, excluded from sums, never shown as $0 | Shares | Position changeShare change is available in the separate comparison view; it is not joined into this position list. | Wt | CongressThe congressional transaction join is unavailable in this build. |
|---|---|---|---|---|---|---|---|---|
| — | AUPHverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | AURINIA PHARMACEUTICALS INC AURINIA PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $181M | 12,229,500 | — | 9.2% | — | |
| — | CELCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CELCUITY INC CELCUITY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $120M | 1,050,000 | — | 6.1% | — | |
| — | MIRMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | MIRUM PHARMACEUTICALS INC MIRUM PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $114M | 1,236,027 | — | 5.8% | — | |
| — | — | GALAPAGOS NV GALAPAGOS NV · SPON ADR CUSIP 36315X101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $114M | 3,785,991 | — | 5.8% | — | |
| — | SPYverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | STATE STR SPDR S&P 500 ETF T STATE STR SPDR S&P 500 ETF T · TR UNIT CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $109M | 168,000 | — | 5.5% | — | |
| — | KNSAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | KINIKSA PHARMACEUTICALS INTL KINIKSA PHARMACEUTICALS INTL · ORD SHS CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $109M | 2,259,889 | — | 5.5% | — | |
| — | — | CAPRICOR THERAPEUTICS INC CAPRICOR THERAPEUTICS INC · COM NEW CUSIP 14070B309 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $103M | 3,399,900 | — | 5.2% | — | |
| — | PTCTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PTC THERAPEUTICS INC PTC THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $102M | 1,500,000 | — | 5.2% | — | |
| — | SYREverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | SPYRE THERAPEUTICS INC SPYRE THERAPEUTICS INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $95.4M | 1,892,200 | — | 4.8% | — | |
| — | — | KALVISTA PHARMACEUTICALS INC KALVISTA PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $92.1M | 4,573,530 | — | 4.7% | — | |
| — | — | COMPASS THERAPEUTICS INC COMPASS THERAPEUTICS INC · COM CUSIP 20454B104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $88.8M | 16,790,809 | — | 4.5% | — | |
| — | TARSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TARSUS PHARMACEUTICALS INC TARSUS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $83.4M | 1,188,624 | — | 4.2% | — | |
| — | IMCRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IMMUNOCORE HLDGS PLC IMMUNOCORE HLDGS PLC · ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $79.9M | 2,649,368 | — | 4.1% | — | |
| — | ANABverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ANAPTYSBIO INC ANAPTYSBIO INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $73.8M | 1,330,879 | — | 3.7% | — | |
| — | CORTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CORCEPT THERAPEUTICS INC CORCEPT THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $60.5M | 1,500,000 | — | 3.1% | — | |
| — | ANIPverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ANI PHARMACEUTICALS INC ANI PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $54.4M | 707,500 | — | 2.8% | — | |
| — | INSMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INSMED INC INSMED INC · COM PAR $.01 CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $42.5M | 260,000 | — | 2.2% | — | |
| — | BNTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BIONTECH SE BIONTECH SE · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $41.8M | 470,000 | — | 2.1% | — | |
| — | — | VIRIDIAN THERAPEUTICS INC VIRIDIAN THERAPEUTICS INC · COM CUSIP 92790C104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $35.1M | 1,792,626 | — | 1.8% | — | |
| — | — | ATEA PHARMACEUTICALS INC ATEA PHARMACEUTICALS INC · COM CUSIP 04683R106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $25.9M | 4,814,700 | — | 1.3% | — | |
| — | — | PRECIGEN INC PRECIGEN INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $24.8M | 6,417,500 | — | 1.3% | — | |
| — | DNTHverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DIANTHUS THERAPEUTICS INC DIANTHUS THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $22.2M | 264,692 | — | 1.1% | — | |
| — | — | COMPASS PATHWAYS PLC COMPASS PATHWAYS PLC · SPONSORED ADS CUSIP 20451W101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $22.1M | 4,002,200 | — | 1.1% | — | |
| — | CBIOverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CRESCENT BIOPHARMA INC. CRESCENT BIOPHARMA INC. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $21.3M | 1,160,000 | — | 1.1% | — | |
| — | — | STOKE THERAPEUTICS INC STOKE THERAPEUTICS INC · COM CUSIP 86150R107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $16.3M | 500,000 | — | 0.8% | — | |
| — | VKTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VIKING THERAPEUTICS INC VIKING THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $16.3M | 500,000 | — | 0.8% | — | |
| — | — | IDEAYA BIOSCIENCES INC IDEAYA BIOSCIENCES INC · COM CUSIP 45166A102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $15.0M | 450,000 | — | 0.8% | — | |
| — | NUVBverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NUVATION BIO INC NUVATION BIO INC · COM CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.5M | 3,149,557 | — | 0.7% | — | |
| — | — | PLIANT THERAPEUTICS INC PLIANT THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $7.7M | 6,143,132 | — | 0.4% | — | |
| — | — | JOURNEY MED CORP JOURNEY MED CORP · COM CUSIP 48115J109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $7.6M | 1,610,000 | — | 0.4% | — | |
| — | — | JANUX THERAPEUTICS INC JANUX THERAPEUTICS INC · COM CUSIP 47103J105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $7.0M | 500,000 | — | 0.4% | — | |
| — | BIIBverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BIOGEN INC BIOGEN INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.4M | 35,000 | — | 0.3% | — | |
| — | — | UROGEN PHARMA LTD UROGEN PHARMA LTD · COM CUSIP M96088105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.3M | 350,000 | — | 0.3% | — | |
| — | ARVNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ARVINAS INC ARVINAS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.7M | 538,658 | — | 0.3% | — | |
| — | — | PMV PHARMACEUTICALS INC PMV PHARMACEUTICALS INC · COM CUSIP 69353Y103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.3M | 4,245,085 | — | 0.3% | — | |
| — | MRNAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | MODERNA INC MODERNA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.1M | 100,000 | — | 0.3% | — | |
| — | — | HERON THERAPEUTICS INC HERON THERAPEUTICS INC · COM CUSIP 427746102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.0M | 6,250,000 | — | 0.3% | — | |
| — | — | KEZAR LIFE SCIENCES INC KEZAR LIFE SCIENCES INC · COM NEW CUSIP 49372L209 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $4.9M | 664,314 | — | 0.3% | — | |
| — | WVEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | WAVE LIFE SCIENCES LTD WAVE LIFE SCIENCES LTD · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $4.4M | 600,000 | — | 0.2% | — | |
| — | — | LENZ THERAPEUTICS INC LENZ THERAPEUTICS INC · COM CUSIP 52635N103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $4.1M | 451,114 | — | 0.2% | — | |
| — | — | AGIOS PHARMACEUTICALS INC AGIOS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.4M | 100,000 | — | 0.2% | — | |
| — | ERASverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ERASCA INC ERASCA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.2M | 200,000 | — | 0.2% | — | |
| — | — | COHERUS ONCOLOGY INC COHERUS ONCOLOGY INC · COM CUSIP 19249H103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.2M | 1,886,748 | — | 0.2% | — | |
| — | — | NKARTA INC NKARTA INC · COM CUSIP 65487U108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.1M | 1,480,823 | — | 0.2% | — | |
| — | — | ALTIMMUNE INC ALTIMMUNE INC · COM NEW CUSIP 02155H200 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.1M | 666,022 | — | 0.1% | — | |
| — | — | EVOLUS INC EVOLUS INC · COM CUSIP 30052C107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.0M | 483,021 | — | 0.1% | — | |
| — | — | ABEONA THERAPEUTICS INC ABEONA THERAPEUTICS INC · COM NEW CUSIP 00289Y206 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.8M | 400,000 | — | 0.1% | — | |
| — | — | FATE THERAPEUTICS INC FATE THERAPEUTICS INC · COM CUSIP 31189P102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.4M | 1,167,773 | — | 0.1% | — | |
| — | — | NEUMORA THERAPEUTICS INC. NEUMORA THERAPEUTICS INC. · COM CUSIP 640979100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $858K | 439,878 | — | 0.0% | — | |
| — | — | LEXICON PHARMACEUTICALS INC LEXICON PHARMACEUTICALS INC · COM NEW CUSIP 528872302 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $624K | 399,700 | — | 0.0% | — | |
| — | — | ROCKET PHARMACEUTICALS INC ROCKET PHARMACEUTICALS INC · COM CUSIP 77313F106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $358K | 100,000 | — | 0.0% | — |
1–51 of 51 positions · page 1 of 1
every row this filer reported for the quarter, as it reported it — cross-filer de-duplication is applied to issuer totals elsewhere and never deletes a row here
A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗
13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.
Positions are quarter-end snapshots filed up to 45 days late — not current holdings. A position may have been changed or closed before you ever see it, and is older still by however long ago that quarter ended.
Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars with unit_basis carried on every record.
Affiliated managers may report the same position (otherManager), so one position can appear under more than one filer.
Positions under confidential treatment may be omitted until a later amendment discloses them.
These are disclosures, not investment advice (ARCHITECTURE.md §5.2 / M2-CONTRACT §5).